Enovis Corp (ENOV)

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Ticker
ENOV
Exchange
NYSE
Sector
Healthcare
Industry
Medical Devices
Market cap
$1.57B
52-week range
$16.70 - $32.41

Valuation

Share price
$27.16 (close of Nov 6, 2026)
P/E (TTM)
-2.94x
Price to book
1.05x
Price to free cash flow
22.53x
Enterprise value
$2.84B
Book value per share
$25.92

Price performance

PeriodChange
1 day-5.10%
5 days+36.41%
1 month+49.23%
3 months+3.23%
6 months+9.30%
Year to date+1.95%
1 year-4.43%
3 years-41.42%
5 years-70.21%
10 years-51.58%
All time-24.86%

Short interest

As of
Oct 15, 2026
Short % of float
24.18%
Shares short
11.70M
Days to cover
8.68
Change since prior report
+10.79%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-79.39%
Return on invested capital
-39.15%
Return on assets
-30.89%
Return on capital employed
-34.74%
Gross margin
59.84%
Net margin
-52.69%
EBITDA margin
9.78%
Revenue growth
6.66%

Cash flow and balance sheet

Free cash flow yield (TTM)
4.44%
Current ratio
2.15x
Net debt to EBITDA
-7.11x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$2.25B
Cost of revenue
$902.79M
Gross profit
$1.35B
EBITDA
$219.89M
Net income
-$1.18B
Earnings per share
$-20.75
Research and development
$120.33M
Interest expense
$34.82M
Shares outstanding
57.07M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$2.25B$1.35B-$1.18B-$20.75
2024-12-31$2.11B$1.18B-$825.49M-$14.93
2023-12-31$1.71B$990.78M-$33.26M-$0.61
2022-12-31$1.56B$869.38M-$13.29M-$0.25
2021-12-31$1.43B$777.67M$71.66M$1.40
2020-12-31$1.12B$603.64M$42.63M$0.93
2019-12-31$3.33B$1.40B-$527.65M-$11.67
2018-12-31$2.19B$729.38M$140.20M$3.51
2017-12-31$1.94B$671.58M$151.09M$3.69
2016-12-31$3.19B$992.38M$128.11M$3.12

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3159.84%-52.69%-79.39%-39.15%
2024-12-3156.02%-39.17%-32.19%-19.55%
2023-12-3158.04%-1.95%-0.97%-1.32%
2022-12-3155.62%-0.85%-0.39%-1.88%
2021-12-3154.53%5.02%1.54%-0.64%
2020-12-3153.86%3.80%1.19%-0.56%
2019-12-3142.11%-15.86%-15.12%2.94%
2018-12-3133.26%6.39%4.03%3.24%
2017-12-3134.67%7.80%4.05%2.78%
2016-12-3131.15%4.02%4.14%4.22%

Cash and debt by year

Period endCashDebt
2025-12-31$36.39M$1.26B
2024-12-31$48.17M$1.31B
2023-12-31$36.19M$466.16M
2022-12-31$24.30M$40.00M
2021-12-31$680.25M$2.08B
2020-12-31$97.07M$2.20B
2019-12-31$109.63M$2.28B
2018-12-31$77.15M$1.19B
2017-12-31$411.63M$1.06B
2016-12-31$208.81M$1.29B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$19.92M$32.92M
2024-12-31-$67.21M$29.66M
2023-12-31$12.77M$34.06M
2022-12-31-$161.31M$38.95M
2021-12-31$251.86M$35.35M
2020-12-31$187.15M$28.91M
2019-12-31$5.55M$21.96M
2018-12-31$156.72M$25.10M
2017-12-31$150.00M$21.55M
2016-12-31$183.72M$19.02M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-05Sep 2026$0.64
2026-08-06Jun 2026$0.79
2026-05-07Mar 2026$0.82
2026-02-26Dec 2025$0.81
2025-11-06Sep 2025$0.67
2025-08-07Jun 2025$0.74
2025-05-08Mar 2025$0.74
2025-02-26Dec 2024$0.92

Filings and sources

Company website
enovis.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · GE HealthCare Technologies Inc. (GEHC) · Dexcom Inc (DXCM) · STERIS plc (STE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades